Omeros amends royalty deal with DRI, receives $115M for expanded OMIDRIA royalty sale

OMEROS CORP

Omeros received $115M cash from DRI Healthcare Acquisitions LP for an expanded interest in OMIDRIA royalties.
Amendment eliminates annual caps on DRI royalties; DRI now receives all U.S. net sales royalties from Jan 2024 through Dec 2031.
Omeros eligible for two milestone payments of up to $27.5M each in Jan 2026 and Jan 2028 based on U.S. sales thresholds.
Omeros retains all non-U.S. OMIDRIA royalties from Jan 2024 and all global royalties after Dec 2031; royalty term extends to 2035 in U.S.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.